Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000793420 | SCV000932771 | likely benign | Hereditary spastic paraplegia 30; Neuropathy, hereditary sensory, type 2C; Intellectual disability, autosomal dominant 9 | 2025-01-13 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001000675 | SCV001157705 | uncertain significance | not specified | 2018-07-10 | criteria provided, single submitter | clinical testing | The KIF1A c.4195G>C; p.Glu1399Gln variant (rs376432305), to our knowledge, is not reported in the medical literature or gene specific databases. This variant is found in the general population with an overall allele frequency of 0.005% (13 / 202,520 alleles) in the Genome Aggregation Database. The glutamic acid at codon 1399 is highly conserved but computational analyses (SIFT: damaging, PolyPhen-2: benign) predict conflicting effects of this variant on protein structure/function. Due to limited information, the clinical significance of the p.Glu1399Gln variant is uncertain at this time. |
Ce |
RCV001310786 | SCV001500724 | uncertain significance | not provided | 2023-12-01 | criteria provided, single submitter | clinical testing | KIF1A: PP3 |
Gene |
RCV001310786 | SCV002567697 | uncertain significance | not provided | 2022-08-08 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002332590 | SCV002637573 | uncertain significance | Inborn genetic diseases | 2021-03-29 | criteria provided, single submitter | clinical testing | The p.E1500Q variant (also known as c.4498G>C), located in coding exon 42 of the KIF1A gene, results from a G to C substitution at nucleotide position 4498. The glutamic acid at codon 1500 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |